SI3402790T1 - Spiroheptan salicilamidi in povezane spojine kot rock inhibitorji - Google Patents
Spiroheptan salicilamidi in povezane spojine kot rock inhibitorjiInfo
- Publication number
- SI3402790T1 SI3402790T1 SI201730984T SI201730984T SI3402790T1 SI 3402790 T1 SI3402790 T1 SI 3402790T1 SI 201730984 T SI201730984 T SI 201730984T SI 201730984 T SI201730984 T SI 201730984T SI 3402790 T1 SI3402790 T1 SI 3402790T1
- Authority
- SI
- Slovenia
- Prior art keywords
- rock
- inhibitors
- related compounds
- salicylamides
- spiroheptane
- Prior art date
Links
- -1 Spiroheptane salicylamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000011435 rock Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662278122P | 2016-01-13 | 2016-01-13 | |
| EP17701785.2A EP3402790B1 (en) | 2016-01-13 | 2017-01-13 | Spiroheptane salicylamides and related compounds as inhibitors of rock |
| PCT/US2017/013323 WO2017123860A1 (en) | 2016-01-13 | 2017-01-13 | Spiroheptane salicylamides and related compounds as inhibitors of rock |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3402790T1 true SI3402790T1 (sl) | 2022-01-31 |
Family
ID=57907009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730984T SI3402790T1 (sl) | 2016-01-13 | 2017-01-13 | Spiroheptan salicilamidi in povezane spojine kot rock inhibitorji |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US10611776B2 (enExample) |
| EP (2) | EP3954681A1 (enExample) |
| JP (2) | JP6976953B2 (enExample) |
| KR (1) | KR102725741B1 (enExample) |
| CN (1) | CN108699038B (enExample) |
| AR (1) | AR107354A1 (enExample) |
| AU (2) | AU2017206820B2 (enExample) |
| BR (1) | BR112018013780B1 (enExample) |
| CA (1) | CA3010900A1 (enExample) |
| CL (1) | CL2018001899A1 (enExample) |
| CO (1) | CO2018008173A2 (enExample) |
| CY (1) | CY1124858T1 (enExample) |
| EA (1) | EA036172B1 (enExample) |
| ES (1) | ES2898698T3 (enExample) |
| HR (1) | HRP20211888T1 (enExample) |
| HU (1) | HUE057455T2 (enExample) |
| IL (1) | IL260448B (enExample) |
| LT (1) | LT3402790T (enExample) |
| MA (2) | MA55633A (enExample) |
| MX (2) | MX382434B (enExample) |
| PL (1) | PL3402790T3 (enExample) |
| PT (1) | PT3402790T (enExample) |
| RS (1) | RS62690B1 (enExample) |
| SG (1) | SG11201805927YA (enExample) |
| SI (1) | SI3402790T1 (enExample) |
| SM (1) | SMT202100660T1 (enExample) |
| TW (1) | TWI730032B (enExample) |
| UY (1) | UY37073A (enExample) |
| WO (1) | WO2017123860A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3242873B1 (en) | 2015-01-09 | 2020-07-22 | Bristol-Myers Squibb Company | Cyclic ureas as inhibitors of rock |
| US10112929B2 (en) | 2015-03-09 | 2018-10-30 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| TWI730032B (zh) * | 2016-01-13 | 2021-06-11 | 美商必治妥美雅史谷比公司 | 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物 |
| HUE051642T2 (hu) | 2016-01-13 | 2021-03-01 | Gruenenthal Gmbh | 8-amino-2-oxo-1,3-diaza-spiro-[4,5]-dekán származékok |
| LT3402785T (lt) | 2016-01-13 | 2020-04-10 | Grünenthal GmbH | 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai |
| EA202190281A1 (ru) | 2016-01-13 | 2021-09-01 | Грюненталь Гмбх | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана |
| PL3402784T3 (pl) | 2016-01-13 | 2020-09-21 | Grünenthal GmbH | Pochodne 3-((hetero-)arylo)-alkilo-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekanu |
| ES2947636T3 (es) | 2016-03-16 | 2023-08-14 | Kura Oncology Inc | Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso |
| JP6987792B2 (ja) | 2016-05-27 | 2022-01-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ｒｏｃｋ阻害剤としてのトリアゾロンおよびテトラゾロン |
| KR102449652B1 (ko) | 2016-07-07 | 2022-09-29 | 브리스톨-마이어스 스큅 컴퍼니 | Rock의 억제제로서의 스피로-융합 시클릭 우레아 |
| JP7113810B2 (ja) | 2016-07-07 | 2022-08-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのスピロラクタム |
| JP6903731B2 (ja) | 2016-07-07 | 2021-07-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力で選択的なｒｏｃｋ阻害剤としてのラクタム、環状尿素、およびカルバメート、およびトリアゾロン誘導体 |
| JP7191826B2 (ja) | 2016-11-30 | 2022-12-19 | ブリストル－マイヤーズ スクイブ カンパニー | 三環式ｒｈｏキナーゼ阻害剤 |
| TW201908293A (zh) * | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| ES2951212T3 (es) | 2017-07-12 | 2023-10-18 | Bristol Myers Squibb Co | Fenilacetamidas como inhibidores de ROCK |
| EP3652165B1 (en) * | 2017-07-12 | 2021-08-25 | Bristol-Myers Squibb Company | Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure |
| US12060341B2 (en) | 2017-07-12 | 2024-08-13 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as ROCK inhibitors |
| JP7313331B2 (ja) | 2017-07-12 | 2023-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのスピロヘプタニルヒダントイン |
| US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
| WO2019089868A1 (en) | 2017-11-03 | 2019-05-09 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
| KR102815312B1 (ko) * | 2018-04-17 | 2025-05-30 | 템페스트 테라퓨틱스, 인크. | 비시클릭 카르복스아미드 및 그의 사용 방법 |
| EP4431596A1 (en) | 2021-11-11 | 2024-09-18 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
| JP2023120893A (ja) | 2022-02-18 | 2023-08-30 | キヤノン株式会社 | 保持装置、リソグラフィ装置、および物品製造方法 |
| CN119698408A (zh) * | 2022-07-12 | 2025-03-25 | 安道麦马克西姆有限公司 | 制备取代的苯甲酰胺的方法 |
| WO2024229439A2 (en) * | 2023-05-03 | 2024-11-07 | The University Of Chicago | Inhibitors of nsun1- and nsun2-mediated active structures |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025247783A1 (en) | 2024-05-29 | 2025-12-04 | Syngenta Crop Protection Ag | Pesticidally active dihydro-benzoxazinone compounds |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200815398A (en) * | 2006-06-08 | 2008-04-01 | Ube Industries | A novel indazole derivative having spirocyclic structure in the side chain |
| EP2526948A1 (en) | 2006-09-20 | 2012-11-28 | Aerie Pharmaceuticals, Inc. | RHO kinase inhibitors |
| WO2008077551A1 (en) | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Cycloalkylamine substituted isoquinolone derivatives |
| CL2007003874A1 (es) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| CA2710447A1 (en) * | 2007-12-26 | 2009-07-02 | Sanofi-Aventis | Process for the preparation of 6-substituted-1-(2h)-isoquinolinones |
| SG10201602857UA (en) | 2010-11-15 | 2016-05-30 | Abbvie Inc | NAMPT And Rock Inhibitors |
| WO2014113620A2 (en) | 2013-01-18 | 2014-07-24 | Bristol-Myers Squibb Company | Phthalazinones and isoquinolinones as rock inhibitors |
| TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物 |
| WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| JP6522602B2 (ja) | 2013-07-02 | 2019-05-29 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体 |
| TW201506024A (zh) | 2013-07-02 | 2015-02-16 | 必治妥美雅史谷比公司 | 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物 |
| US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| WO2016028971A1 (en) | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| EP3242873B1 (en) | 2015-01-09 | 2020-07-22 | Bristol-Myers Squibb Company | Cyclic ureas as inhibitors of rock |
| US10112929B2 (en) | 2015-03-09 | 2018-10-30 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| TWI730032B (zh) * | 2016-01-13 | 2021-06-11 | 美商必治妥美雅史谷比公司 | 作為ｒｏｃｋ抑制劑之螺庚烷水楊酸醯胺及相關化合物 |
| JP6987792B2 (ja) | 2016-05-27 | 2022-01-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ｒｏｃｋ阻害剤としてのトリアゾロンおよびテトラゾロン |
| KR102449652B1 (ko) | 2016-07-07 | 2022-09-29 | 브리스톨-마이어스 스큅 컴퍼니 | Rock의 억제제로서의 스피로-융합 시클릭 우레아 |
| JP7113810B2 (ja) | 2016-07-07 | 2022-08-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのスピロラクタム |
| JP6903731B2 (ja) | 2016-07-07 | 2021-07-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力で選択的なｒｏｃｋ阻害剤としてのラクタム、環状尿素、およびカルバメート、およびトリアゾロン誘導体 |
| JP7191826B2 (ja) | 2016-11-30 | 2022-12-19 | ブリストル－マイヤーズ スクイブ カンパニー | 三環式ｒｈｏキナーゼ阻害剤 |
-
2017
- 2017-01-12 TW TW106101072A patent/TWI730032B/zh active
- 2017-01-12 UY UY0001037073A patent/UY37073A/es unknown
- 2017-01-12 AR ARP170100088A patent/AR107354A1/es unknown
- 2017-01-13 PL PL17701785T patent/PL3402790T3/pl unknown
- 2017-01-13 LT LTEPPCT/US2017/013323T patent/LT3402790T/lt unknown
- 2017-01-13 ES ES17701785T patent/ES2898698T3/es active Active
- 2017-01-13 US US16/067,619 patent/US10611776B2/en active Active
- 2017-01-13 MA MA055633A patent/MA55633A/fr unknown
- 2017-01-13 SI SI201730984T patent/SI3402790T1/sl unknown
- 2017-01-13 AU AU2017206820A patent/AU2017206820B2/en active Active
- 2017-01-13 HU HUE17701785A patent/HUE057455T2/hu unknown
- 2017-01-13 BR BR112018013780-4A patent/BR112018013780B1/pt active IP Right Grant
- 2017-01-13 MA MA043862A patent/MA43862A/fr unknown
- 2017-01-13 CA CA3010900A patent/CA3010900A1/en active Pending
- 2017-01-13 PT PT177017852T patent/PT3402790T/pt unknown
- 2017-01-13 KR KR1020187022838A patent/KR102725741B1/ko active Active
- 2017-01-13 CN CN201780015453.3A patent/CN108699038B/zh active Active
- 2017-01-13 WO PCT/US2017/013323 patent/WO2017123860A1/en not_active Ceased
- 2017-01-13 EA EA201891557A patent/EA036172B1/ru not_active IP Right Cessation
- 2017-01-13 SM SM20210660T patent/SMT202100660T1/it unknown
- 2017-01-13 SG SG11201805927YA patent/SG11201805927YA/en unknown
- 2017-01-13 RS RS20211514A patent/RS62690B1/sr unknown
- 2017-01-13 HR HRP20211888TT patent/HRP20211888T1/hr unknown
- 2017-01-13 MX MX2018008219A patent/MX382434B/es unknown
- 2017-01-13 JP JP2018536481A patent/JP6976953B2/ja active Active
- 2017-01-13 EP EP21193297.5A patent/EP3954681A1/en active Pending
- 2017-01-13 EP EP17701785.2A patent/EP3402790B1/en active Active
-
2018
- 2018-07-02 MX MX2021005311A patent/MX2021005311A/es unknown
- 2018-07-05 IL IL260448A patent/IL260448B/en active IP Right Grant
- 2018-07-12 CL CL2018001899A patent/CL2018001899A1/es unknown
- 2018-08-01 CO CONC2018/0008173A patent/CO2018008173A2/es unknown
-
2020
- 2020-01-10 US US16/739,363 patent/US10829501B2/en active Active
-
2021
- 2021-08-26 AU AU2021221872A patent/AU2021221872A1/en not_active Abandoned
- 2021-11-10 JP JP2021182946A patent/JP7268116B2/ja active Active
- 2021-12-09 CY CY20211101084T patent/CY1124858T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260448B (en) | Spiroheptane salicylamides and related compounds as rock inhibitors | |
| IL263163A (en) | Pyridines are converted as inhibitors of dnmt1 | |
| IL261606A (en) | Inhibitors of transfected menin-mll and methods of use | |
| ZA201700304B (en) | Spirocycloheptanes as inhibitors of rock | |
| IL261167A (en) | Heteroaryl pad4 inhibitors | |
| IL267291B (en) | Actonucleotidase inhibitors and methods of using them | |
| ZA201604272B (en) | Inhibitors of glutaminase | |
| IL251584A0 (en) | Dihydropyrrolopyridines ror-gamma inhibitors | |
| IL246902A0 (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
| IL259801A (en) | ezh2 inhibitors and methods of using them | |
| IL279949A (en) | Heterocyclic MCT4 inhibitors | |
| IL257061A (en) | Inhibitors of ezh2 | |
| IL259796A (en) | Aza-benzimidazole inhibitors of pad4 | |
| PL3313833T3 (pl) | Związki i ich zastosowanie w charakterze inhibitorów transferazy n-mirystoilu | |
| EP3405477C0 (en) | TRANSGLUTAMINASE INHIBITORS | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| PT3458448T (pt) | Inibidores fasn para uso no tratamento de esteato-hepatite não-alcoólica | |
| IL247678A0 (en) | Amino-disubstituted azole compounds as tnks1 and/or tnks2 inhibitors | |
| HUE044559T2 (hu) | Lerakódást gátló készítmények és alkalmazási eljárásaik | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| HK1262425A1 (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
| GB201521541D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201521547D0 (en) | New therapeutic uses of enzyme inhibitors | |
| HK1238235A1 (en) | Spirocycloheptanes as inhibitors of rock |